Gemcitabine Exerts a Selective Effect on the Humoral Immune Response Implications for Combination Chemo-immunotherapy

摘要: Most cytotoxic drugs have gross effects on the immune system, such as neutropenia and lymphopenia. However, their tumor-specific responses are unknown. Gemcitabine is a nucleoside analogue that frequently used to treat non-small cell lung cancer. It also active in other malignancies, either alone or combination with cisplatin. Here, we investigate its antigen-specific antitumor immunity using murine tumor line transfected express influenza virus hemagglutinin (HA). CD4(+), CD8(+), B220(+) lymphocyte numbers all decreased during chemotherapy (120 microg/g, i.p., every third day for five doses), but B cells were selectively depleted. induced profound suppression of IgG antibody response HA, this was unrelated size. In contrast, vitro T-lymphocyte recall class I- II-restricted dominant peptide epitopes HA enhanced tumor-bearing, gemcitabine-treated mice. We found gemcitabine >2-fold more potent ability inhibit B-lymphocyte proliferation compared proliferation. Thus, does not appear be detrimental specific cellular may useful chemo-immunotherapy protocols. vaccination protocols requiring humoral maximal efficacy compromised patients treated gemcitabine.